JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

Certara Inc

Deschisă

SectorSănătate

5.99 0.17

Rezumat

Modificarea prețului

24h

Curent

Minim

5.8

Maxim

6.01

Indicatori cheie

By Trading Economics

Venit

-7.4M

-5.9M

Vânzări

-968K

104M

P/E

Medie Sector

100.714

67.147

Marjă de profit

-5.688

Angajați

1,515

EBITDA

8.6M

32M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+38.44% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-77M

957M

Deschiderea anterioară

5.82

Închiderea anterioară

5.99

Sentimentul știrilor

By Acuity

50%

50%

201 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 23:53 UTC

Câștiguri

Naver Posts Weaker First-Quarter Earnings

29 apr. 2026, 23:41 UTC

Acțiuni populare

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr. 2026, 23:55 UTC

Câștiguri

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr. 2026, 23:54 UTC

Câștiguri

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr. 2026, 23:52 UTC

Câștiguri

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr. 2026, 23:51 UTC

Câștiguri

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss Narrows>000002.SZ

29 apr. 2026, 23:18 UTC

Câștiguri

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr. 2026, 23:17 UTC

Câștiguri

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr. 2026, 23:13 UTC

Câștiguri

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr. 2026, 23:12 UTC

Câștiguri

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr. 2026, 23:04 UTC

Câștiguri

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr. 2026, 23:04 UTC

Câștiguri

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

38.44% sus

Prognoză pe 12 luni

Medie 8.5 USD  38.44%

Maxim 10 USD

Minim 7 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

3

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

201 / 348 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat